ResearcherHarvard UniversityActive in the last 2 years
Hannah Johnson Roberts
Matched on ORCID iD 0000-0003-2110-9542; OpenAlex author ID A5072802522, A5083858630, A5104182364. Sources: OpenAlex.
Their work
- Papers
- 8
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 63
2024: 4 papers · 2025: 2 papers · 2026: 2 papers
Papers 8
- Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2026.3716↗
- Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic cancer Co-author DOI 10.64898/2026.08.06.26359422↗
- The Pdgfd-Pdgfrb axis orchestrates tumor-nerve crosstalk in pancreatic cancer Co-author DOI 10.1101/2025.08.26.672505↗
- Evaluating CBCT-Guided Adaptive Radiotherapy for Pancreatic Cancer Using Synthetic CBCT Data. Co-author DOI 10.3390/curroncol32020060↗
- Spatially resolved analysis of pancreatic cancer identifies therapy-associated remodeling of the tumor microenvironment. Co-author DOI 10.1038/s41588-024-01890-9↗
- Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006131↗
- Establishing a Role for Local Therapy in Oligometastatic Pancreatic Cancer. Co-author DOI 10.1200/jco-24-01264↗
- Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-human translational studies. Co-author DOI 10.7150/thno.100116↗
Closest collaborators
The 25 strongest of 63 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jennifer Yon-Li Wo · 7 shared papers, 2024–2026 · strength 1.48
- Paper Establishing a Role for Local Therapy in Oligometastatic Pancreatic Cancer. DOI 10.1200/jco-24-01264↗
- Paper Evaluating CBCT-Guided Adaptive Radiotherapy for Pancreatic Cancer Using Synthetic CBCT Data. DOI 10.3390/curroncol32020060↗
- Paper Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. DOI 10.1001/jamasurg.2026.3716↗
- Theodore Sunki Hong · 7 shared papers, 2024–2026 · strength 1.27
- Paper Evaluating CBCT-Guided Adaptive Radiotherapy for Pancreatic Cancer Using Synthetic CBCT Data. DOI 10.3390/curroncol32020060↗
- Paper Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. DOI 10.1001/jamasurg.2026.3716↗
- Paper Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic… DOI 10.64898/2026.08.06.26359422↗
- Colin D. Weekes · 5 shared papers, 2024–2026 · strength 1.06
- Paper Establishing a Role for Local Therapy in Oligometastatic Pancreatic Cancer. DOI 10.1200/jco-24-01264↗
- Paper Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. DOI 10.1001/jamasurg.2026.3716↗
- Paper Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic… DOI 10.64898/2026.08.06.26359422↗
- Motaz Qadan · 4 shared papers, 2024–2026 · strength 0.66
- Paper Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. DOI 10.1001/jamasurg.2026.3716↗
- Paper Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients With Pancreatic Ductal Adenoc… DOI 10.1097/sla.0000000000006131↗
- Paper Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-huma… DOI 10.7150/thno.100116↗
- David Tsai Ting · 4 shared papers, 2024–2026 · strength 0.64
- Paper Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic… DOI 10.64898/2026.08.06.26359422↗
- Paper The Pdgfd-Pdgfrb axis orchestrates tumor-nerve crosstalk in pancreatic cancer DOI 10.1101/2025.08.26.672505↗
- Paper Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-huma… DOI 10.7150/thno.100116↗
- David P. Ryan · 3 shared papers, 2024–2026 · strength 0.55
- Paper Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. DOI 10.1001/jamasurg.2026.3716↗
- Paper Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic… DOI 10.64898/2026.08.06.26359422↗
- Paper Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients With Pancreatic Ductal Adenoc… DOI 10.1097/sla.0000000000006131↗
- Lawrence Scott Blaszkowsky · 3 shared papers, 2024–2026 · strength 0.55
- Paper Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. DOI 10.1001/jamasurg.2026.3716↗
- Paper Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic… DOI 10.64898/2026.08.06.26359422↗
- Paper Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients With Pancreatic Ductal Adenoc… DOI 10.1097/sla.0000000000006131↗
- Aparna R. Parikh · 3 shared papers, 2024–2026 · strength 0.50
- Paper Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic… DOI 10.64898/2026.08.06.26359422↗
- Paper Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients With Pancreatic Ductal Adenoc… DOI 10.1097/sla.0000000000006131↗
- Paper Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-huma… DOI 10.7150/thno.100116↗
- Priyadarshini Pathak · 2 shared papers, 2024–2026 · strength 0.37
- Keith D. Lillemoe · 2 shared papers, 2024–2026 · strength 0.37
- Carlos Fernández-del Castillo · 2 shared papers, 2024–2026 · strength 0.35
- William L. Hwang · 2 shared papers, 2024–2025 · strength 0.30
- Nicholas J Caldwell · 2 shared papers, 2024–2025 · strength 0.30
- Dennis H. Gong · 2 shared papers, 2024–2025 · strength 0.30
- Carina Shiau · 2 shared papers, 2024–2025 · strength 0.30
- Jimmy A. Guo · 2 shared papers, 2024–2025 · strength 0.30
- Mari A. Mino-Kenudson · 2 shared papers, 2024–2025 · strength 0.30
- Ralph Weissleder · 2 shared papers, 2024–2025 · strength 0.30
- Tyler Jacks · 2 shared papers, 2024–2025 · strength 0.30
- Sven Olberg · 1 shared paper, 2025 · strength 0.27
- J. Pursley · 1 shared paper, 2025 · strength 0.27
- Giulio Belfiori · 1 shared paper, 2026 · strength 0.20
- Stefano Partelli · 1 shared paper, 2026 · strength 0.20
- Federico De Stefano · 1 shared paper, 2026 · strength 0.20
- Nicolò Pecorelli · 1 shared paper, 2026 · strength 0.20
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.